Open AccessSerum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Author(s) -
KlausPeter Dieckmann,
Arlo Radtke,
Lajos Gergely,
Cord Matthies,
Petra Anheuser,
Ulrike Eckardt,
Jörg Sommer,
Friedemann Zengerling,
Emanuela Trenti,
Renate Pichler,
Hanjo Belz,
Stefan Zastrow,
Alexander Winter,
Sebastian Melchior,
Johannes Hammel,
Jennifer Kranz,
Marius Bolten,
Susanne Krege,
Björn Haben,
Wolfgang Loidl,
Christian Ruf,
Julia Heinzelbecker,
Axel Heidenreich,
JannFrederik Cremers,
Christoph Oing,
Thomas Hermanns,
Christian Daniel Fankhauser,
Silke Gillessen,
Hermann Reichegger,
Richard Cathomas,
Martin Pichler,
Marcus Hentrich,
Klaus Eredics,
Anja Lorch,
Christian Wülfing,
Sven Peine,
Werner Wosniok,
Carsten Bokemeyer,
Gazanfer Belge
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.18.01480
Subject(s) - seminoma , human chorionic gonadotropin , medicine , biomarker , orchiectomy , testicular cancer , germ cell tumors , population , stage (stratigraphy) , prospective cohort study , receiver operating characteristic , lactate dehydrogenase , oncology , pathology , gastroenterology , cancer , biology , hormone , chemotherapy , paleontology , biochemistry , environmental health , enzyme
Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the usefulness of this test as a novel biomarker for GCT.